2006
DOI: 10.1039/b512267h
|View full text |Cite
|
Sign up to set email alerts
|

The Morita–Baylis–Hillman adducts of β-aryl nitroethylenes with other activated alkenes: synthesis and anticancer activity studies

Abstract: The Morita-Baylis-Hillman (MBH) adducts of beta-aryl nitroethylenes with methyl vinyl ketone (MVK) and acrylate, formed in moderate to good yield when mediated by imidazole/LiCl in THF at room temperature, inhibit HeLa cell proliferation by binding to tubulin.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
37
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 74 publications
(38 citation statements)
references
References 21 publications
1
37
0
Order By: Relevance
“…In the above scenario, our endeavors to achieve reactions between nitroalkenes and various electrophiles such as formaldehyde, [10][11] activated carbonyl compounds [12] / imines [13] /alkenes, [14] and azodicarboxylates [15] in the presence of imidazole or DMAP as the catalyst have met with success in recent years. The anti-cancer activities exhibited by many MBH adducts of nitroalkenes at low micromolar concentrations, through targeting of tubulins/microtubules, [11,13,14] and the potential application of MBH adducts as valuable intermediates in the synthesis of amino alcohols, amino acids, and heterocycles encouraged us to expand the scope of the MBH reaction by introducing aliphatic nitroalkenes and aromatic nitrodienes as substrates for the first time.…”
Section: Introductionmentioning
confidence: 98%
See 1 more Smart Citation
“…In the above scenario, our endeavors to achieve reactions between nitroalkenes and various electrophiles such as formaldehyde, [10][11] activated carbonyl compounds [12] / imines [13] /alkenes, [14] and azodicarboxylates [15] in the presence of imidazole or DMAP as the catalyst have met with success in recent years. The anti-cancer activities exhibited by many MBH adducts of nitroalkenes at low micromolar concentrations, through targeting of tubulins/microtubules, [11,13,14] and the potential application of MBH adducts as valuable intermediates in the synthesis of amino alcohols, amino acids, and heterocycles encouraged us to expand the scope of the MBH reaction by introducing aliphatic nitroalkenes and aromatic nitrodienes as substrates for the first time.…”
Section: Introductionmentioning
confidence: 98%
“…The anti-cancer activities exhibited by many MBH adducts of nitroalkenes at low micromolar concentrations, through targeting of tubulins/microtubules, [11,13,14] and the potential application of MBH adducts as valuable intermediates in the synthesis of amino alcohols, amino acids, and heterocycles encouraged us to expand the scope of the MBH reaction by introducing aliphatic nitroalkenes and aromatic nitrodienes as substrates for the first time. This report is the full version of our preliminary communication relating to the reactions between aromatic nitroalkenes and various activated non-enolizable carbonyl compounds.…”
Section: Introductionmentioning
confidence: 99%
“…A wide range of functional groups can be introduced in MBH adducts by the selection of three relevant constituents namely, activated alkene, electrophile and catalyst . MBH adducts such as α‐hydroxymethylated and α‐aminoalkylated conjugated nitroalkenes has been found to inhibit human cervical cancer cells . Moreover, derivatives of MBH adducts have also exhibited hypolipidemic, antifungal, antitumoral and several other activities in the biological sphere .…”
Section: Introductionmentioning
confidence: 99%
“…For these reasons, to our best knowledge, no enantioselective intermolecular crossed-conjugate addition has been reported. [8] To study this transformation, our group investigated the double Michael addition of nitroalkenes and enones. With a b-alkyl group on the nitroalkene, the crossed-conjugate addition was successfully achieved through an irreversible b-hydride elimination (Scheme 2 A).…”
mentioning
confidence: 99%